Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

Aaron Kaviani; Rose Khavari

doi:10.1016/j.ucl.2017.04.012

Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

Aaron Kaviani, Rose Khavari

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.

Original language	English (US)
Pages (from-to)	463-474
Number of pages	12
Journal	Urologic Clinics of North America
Volume	44
Issue number	3
DOIs	https://doi.org/10.1016/j.ucl.2017.04.012
State	Published - Aug 2017

Keywords

Botulinum toxin
Detrusor overactivity
Multiple sclerosis
Myelomeningocele
Neurogenic
Overactive bladder
Parkinson's disease
Urinary incontinence

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.ucl.2017.04.012

Cite this

@article{4048904a2e5e4786a87f6b5cc6f5bd7f,

title = "Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity",

abstract = "Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.",

keywords = "Botulinum toxin, Detrusor overactivity, Multiple sclerosis, Myelomeningocele, Neurogenic, Overactive bladder, Parkinson's disease, Urinary incontinence",

author = "Aaron Kaviani and Rose Khavari",

note = "Funding Information: Disclosure: R. Khavari is a scholar supported in part by NIH grant K12 DK0083014, the multidisciplinary K12 urologic research (KURe) career development program grant awarded to Dolores J Lamb by the national institute of diabetes and digestive and kidney diseases (NIDDK) (12 DK083014-09), national institutes of health (NIH). Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = aug,

doi = "10.1016/j.ucl.2017.04.012",

language = "English (US)",

volume = "44",

pages = "463--474",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

AU - Kaviani, Aaron

AU - Khavari, Rose

N1 - Funding Information: Disclosure: R. Khavari is a scholar supported in part by NIH grant K12 DK0083014, the multidisciplinary K12 urologic research (KURe) career development program grant awarded to Dolores J Lamb by the national institute of diabetes and digestive and kidney diseases (NIDDK) (12 DK083014-09), national institutes of health (NIH). Publisher Copyright: © 2017 Elsevier Inc.

PY - 2017/8

Y1 - 2017/8

N2 - Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.

AB - Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.

KW - Botulinum toxin

KW - Detrusor overactivity

KW - Multiple sclerosis

KW - Myelomeningocele

KW - Neurogenic

KW - Overactive bladder

KW - Parkinson's disease

KW - Urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=85024093186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024093186&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2017.04.012

DO - 10.1016/j.ucl.2017.04.012

M3 - Review article

C2 - 28716326

AN - SCOPUS:85024093186

SN - 0094-0143

VL - 44

SP - 463

EP - 474

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

IS - 3

ER -

Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this